Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : BPRX Turn around -- Ignore unavailable to you. Want to Upgrade?

To: Cindy B. who wrote (166)	2/15/1999 9:14:00 AM
From: Instock	Read Replies (1) \| Respond to of 197

Personnel Message 7831896

To: Cindy B. who wrote (166)	4/24/1999 11:39:00 AM
From: christopher	Read Replies (1) \| Respond to of 197

I'm starting to like this stock at the current price... Company Press Release SOURCE: Bradley Pharmaceuticals, Inc. CARMOL(R) 40 U.S. Patent Allowed; Studies Under Way; Preliminary Findings Determine CARMOL(R) 40's Superior Efficacy vs. The Leading Prescription Tissue-Softener FAIRFIELD, N.J., April 20 /PRNewswire/ -- Bradley Pharmaceuticals, Inc. (Nasdaq: BPRX - news) today announced it has received a notice of allowance from the U.S. Patent and Trademark Office for a patent for its CARMOL® 40 product line, covering its proprietary urea formulation and use. The patent describes therapeutic applications for CARMOL® 40 for use as an important part of comprehensive dermatological care. Bradley Pharmaceuticals, Inc. Chairman & CEO, Daniel Glassman, stated, ''This patent offers additional protection as we continue to learn more about the product's benefits. Moreover, ongoing studies conducted by Dr. John Ademola of Biometrix Inc., San Francisco, CA, an independent testing laboratory, compare CARMOL® 40 with the leading brand in the category, a product which generates an estimated $50 million in annual revenue. Interim results, based upon two weeks of therapy, are promising in terms of comparative product performance. We expect this study to be completed and published, based upon four weeks of data, within the next few months. CARMOL® 40, as well as many of our other products, are available at leading pharmacies nationwide, including through the internet at drugstore.com.'' Prescription-only CARMOL® 40 (40% urea cream) is a potent tissue softener used in the treatment of thick, severely dry skin and also diseased or damaged nail tissue. The CARMOL® Family of urea-based moisturizers include: CARMOL® 10 (10% Urea) Total Body Lotion ... for dry skin CARMOL® 20 (20% Urea) Extra Strength Enhanced Cream ... for deep moisturizing. CARMOL® HC (Hydrocortisone Acetate Cream USP, 1%), Rx Only ... for dryness plus itching. CARMOL® 40 (40% Urea) Rx Only ... for severely damaged skin and nails. Bradley Pharmaceuticals, Inc. markets brandname products and over-the-counter pharmaceuticals and health-related products throughout the United States as well as in 27 international markets. Bradley Common A Shares (BPRX) are traded on the Nasdaq National Market System.